Dosing adjustments of ponatinib based on responses increased tolerability in patients with chronic myeloid leukemia according to OPTIC.
Back
Achieving Optimal TKI Dosing in Chronic Myeloid Leukemia
Dosing adjustments of ponatinib based on responses increased tolerability in patients with chronic myeloid leukemia according to OPTIC.
Achieving Optimal TKI Dosing in Chronic Myeloid Leukemia
Episodes
All
All
Advertisement
Advertisement
Trending on OncLive
1
Sequencing, Access, and Eligibility Drive CAR T-Cell Therapy Decisions in Early Relapse Myeloma
2
FDA Grants Fast Track Designation to Varsetatug Masetecan for Relapsed/Refractory Metastatic Colorectal Cancer
3
Dr Reiss Binder on the FDA Approval of Daraxonrasib for Metastatic PDAC
4
FDA Grants Fast Track Designation to SYS6090 in Pretreated MSS/pMMR mCRC
5